Using Sperstent® for treating residual lesions in leg arteries

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness and safety of the Sperstent® peripheral spot stent system compared to the Everflex® self-expanding peripheral stent system. It focuses on patients with residual lesions in the femoral and proximal popliteal arteries following balloon angioplasty. The study is prospective and multi-center, involving randomization to ensure unbiased results. Participants will be monitored for improvements in their condition and any potential complications.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18-85 years old, male or female;
* The target lesion is located in the superficial femoral artery or the proximal popliteal artery;
* Peripheral arterial stenosis or occlusive disease with symptoms consistent with the Rutherford classification 2 to 5;
* Estimated life expectancy \>1 year;
* Subject has been informed of and understands the nature of the study and provides signed informed consent to participate in the study.

Angiographic Inclusion Criteria:

* Stenosis rate ≥70% under DSA by visual estimate, or 100% occluded lesion with a total lesion length less than 150mm (by visual estimate);
* Reference vessel diameter is between 3 mm and 7.5 mm, 50mm≤Total cumulative length of target lesions≤250mm; (In the case of bilimb lesions, a single target lesion with one limb meeting the protocol criteria is selected by the investigator; More than 2cm between lesions are considered as 2 lesions);
* After PTA treatment by DCB, there exists residual lesions, such as the target lesion has over 30% residual DS and/or presence of at least one post-PTA dissection (Type A-F) (by visual estimate);
* Patients with unobstructed inflow tract or successfully treated, visual residual stenosis ≤50%;
* Angiography showed at least one outflow tract was unobstructed at the distal end (Stenosis degree ≤70% before intervention).

Exclusion Criteria:

* Target vessel had undergone open surgery such as bypass surgery or the target lesion is in-stent restenosis;
* Patients with serum creatinine \>2.5mg/dl during screening or undergoing long-term hemodialysis or peritoneal dialysis;
* Severe coagulation disorder;
* Patients with major vascular-related diseases, including acute lower extremity ischemia, active disseminated intravascular coagulation, thromboangiitis obliterans, deep vein thrombosis, and aneurysms of therapeutic lateral vessels (deep femur, superficial femur, or popliteal artery);
* A history of major organ failure or other serious illness (including severe coronary heart disease, severe cardiac insufficiency, severe neurosis, or mental illness); Have received or plan organ transplantation, severe gastrointestinal bleeding);
* Myocardial infarction or symptomatic stroke occurred within 3 months prior to enrollment;
* Thrombolysis of target vessel within 72 hours before surgery, did not completely dissolve the thrombus;
* Systemic infection or uncontrolled infection within the target limb;
* Known allergy to contrast agents, nickel or titanium (Nitinol), heparin, aspirin, clopidogrel, anesthetics;
* Women who are pregnant or breast-feeding, or women of childbearing age who have family plans within 1 year;
* Patients who are planning to have major lower limb amputations on the target side of the lesion;
* Endovascular or surgical procedures are performed on the target limb within 30 days before or 30 days after surgery;
* Participating in clinical trials of other medical devices or drugs;
* The investigator considers the patient is not suitable for participation in the clinical trial.

Angiographic Exclusion Criteria:

* Failure of the guidewire to pass through the lesion；
* During the procedure, the target lesions had received or were scheduled to receive volume reduction procedures such as cryogenic angioplasty, laser angioplasty, and percutaneous intracavity plaque gyrotomy；
* The target lesion before stent implantation is thrombotic obliteration, which is not suitable for stent implantation；
* The target lesions were severely calcified and could not fully predilate; Or grade 4 calcification；
* Acute vascular occlusion or acute or subacute thrombosis in the target lesion；
* Stent was implanted into the target vessel before enrollment.

Where it's running

• Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology
  Wuhan, Hubei, China Recruiting
• Nanjing Drum Tower Hospital
  Nanjing, Jiangsu, China Recruiting
• Shanghai East Hospital
  Shanghai, China Recruiting
• Beijing Friendship Hospital, Capital Medical University
  Beijing, Beijing Municipality, China Not yet recruiting
• The First Affiliated Hospital of Chongqing Medical University
  Chongqing, Chongqing Municipality, China Not yet recruiting
• The Second Hospital of Hebei Medical University
  Shijiazhuang, Hebei, China Not yet recruiting

Study contacts

• Study coordinator: Min Zhou, Dr.
• Email: zhouminnju@126.com
• Phone: 01186-25-83106666

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Treatment for patients with blocked femoropopliteal arteries using a new vascular scaffold

  This study is testing a new device to see if it can help people with blocked leg arteries feel better and improve their blood flow.

  Recruiting at 8 sites Efemoral Medical, Inc. · Sydney, New South Wales and 7 other locations · NCT04584632

• Preventing lower limb artery disease in adults with diabetes using a risk-prediction model and HAPA-based nursing

  A risk-prediction model is tested in adults with type 2 diabetes to see if a nursing plan based on the HAPA model can reduce peripheral artery disease in the legs.

  Recruiting Second Affiliated Hospital of Nanchang University · Nanchang, Jang XI · NCT07881588

• Predictors of Major Adverse Limb Events After Iliac Artery Stenting

  This study tests what factors predict serious limb-related problems after iliac artery stenting in adults with peripheral artery disease.

  Recruiting I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio · Milan, Mi · NCT07672249

• New prodrug CG-0255 Besylate vs Plavix in healthy adults

  This study tests whether CG-0255 Besylate works similarly to Plavix® in healthy adults to understand how the two drugs behave in the body.

  Recruiting Phase 1 Shanghai CureGene Pharmaceutical Co., Ltd. · Miami, Florida · NCT07619885

• Radial and Ulnar Access in Vascular Interventions Registry

  This registry tests how often radial or ulnar artery access is used and what happens afterward in routine vascular procedures.

  Recruiting Mersin Medicalpark Hastanesi · Mersin, Mezitli · NCT07614386

• Remote versus in-person 30-second sit-to-stand testing for people with peripheral artery disease

  This project will test whether doing the 30-second sit-to-stand test by video works as well as doing it in person for adults aged 18–65 with Fontaine stage I–II peripheral artery disease who have a smartphone.

  Recruiting Izmir Democracy University · Izmir, Balçova · NCT07497360

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.